Table 2.
Analysis of clinical indexes before and after dapagliflozin treatment in patients with type 2 diabetes mellitus (means ± SD, n = 20)
|
Parameter
|
Before dapagliflozin
|
After dapagliflozin
|
Wilcoxon W
|
P
value
|
| Weight (kg) | 80.600 ± 10.4549 | 74.950 ± 8.9176 | 351.000 | 0.110 |
| BMI | 26.1875 ± 2.1889 | 24.3695 ± 1.8267 | 313.000 | 0.009 |
| Waist circumference (cm) | 98.300 ± 2.4570 | 96.350 ± 2.3402 | 310.50 | 0.007 |
| Hip circumference (cm) | 97.425 ± 3.1131 | 96.975 ± 2.4413 | 395.000 | 0.684 |
| Waist-hip ratio | 1.009350 ± 0.0172 | 0.9937 ± 0.0132 | 311.500 | 0.007 |
| TG | 2.3020 ± 1.7483 | 1.884 ± 1.2172 | 387.000 | 0.534 |
| LDL | 2.9310 ± 0.9873 | 2.8585 ± 1.0440 | 405.000 | 0.892 |
| HDL | 1.0525 ± 0.2722 | 1.0855 ± 0.2457 | 381.000 | 0.432 |
| APOA1 | 1.2450 ± 0.2176 | 1.3630 ± 0.2022 | 334.500 | 0.041 |
| APOB100 | 1.0345 ± 0.3400 | 0.9425 ± 0.2651 | 392.000 | 0.626 |
| CRP | 1.7090 ± 1.1454 | 1.311 ± 0.9305 | 349.000 | 0.098 |
| HbA1c | 8.0550 ± 1.0842 | 6.7500 ± 0.6863 | 277.000 | < 0.001 |
| THCY | 14.6850 ± 3.0387 | 12.030 ± 2.1451 | 311.500 | 0.008 |
| RBP4 | 43.310 ± 8.8547 | 37.150 ± 5.6033 | 315.500 | 0.010 |
| NEFA | 0.4525 ± 0.3246 | 0.8245 ± 0.5849 | 321.500 | 0.017 |
| FCP | 2.7980 ± 0.9510 | 2.2770 ± 0.7903 | 337.000 | 0.048 |
| TC | 4.6830 ± 1.1643 | 4.1950 ± 0.8378 | 347.500 | 0.091 |
| IR | 5.7385 ± 3.2238 | 2.7120 ± 1.7245 | 266.000 | < 0.001 |
| FINS | 13.3500 ± 5.7057 | 8.4905 ± 4.4824 | 289.000 | 0.001 |
| FBP | 9.60 ± 2.437 | 6.80 ± 1.105 | 245.000 | < 0.001 |
| Non-HDL | 3.70 ± 1.129 | 3.05 ± 0.826 | 337.000 | 0.037 |
| HOMA2-insulin | 53.4450 ± 21.1716 | 75.6150 ± 20.339 | 305.000 | 0.005 |
| HOMA2-S% | 44.7950 ± 16.2213 | 61.6750 ± 21.1603 | 310.500 | 0.007 |
| HOMA2-IR | 2.5185 ± 0.9686 | 1.8185 ± 0.7285 | 313.000 | 0.009 |
BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; APOA1: Apolipoprotein A1; ApoB100: Apolipoprotein B100; CRP: C-reactive protein; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; THCY: Homocysteine; RBP4: Retinol binding protein 4; NEFA: Non-esterified fatty acids; FCP: Fasting C-peptide; TC: Total cholesterol; FINS: Fasting plasma insulin level; HOMA2-B: Homeostatic model assessment-beta cell; HOMA2-S%: Homeostatic model assessment-insulin sensitivity; HOMA2-IR: Homeostatic model assessment-insulin resistance.